On September 17, Moderna, Inc. rose 3.05% in regular trading, trading at $148.11 per share, with turnover of $609 million.

On the news front, multiple Wall Street institutions have recently raised their price targets on Moderna in quick succession. The wave of upgrades was driven by positive phase 3 clinical results from Moderna and Merck's co-developed individualized mRNA cancer vaccine for melanoma — the first-ever positive phase 3 data for this class of therapy globally — prompting a broad market reassessment of mRNA technology's value in oncology.

Among the notable moves, Argus Research upgraded Moderna to Buy from Hold with a $180 price target, citing meaningful upside from the cancer vaccine data. Berenberg raised its target to $100 from $45, while Barclays adjusted sharply to $125 from $48 and JPMorgan lifted its target to $77 from $40. UBS, maintaining a Neutral rating with a $150 target, highlighted three near-term individualized neoantigen therapy data readouts as potential stock catalysts, including a phase 3 melanoma update expected at a major conference this fall.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)